Literature DB >> 35235733

Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity.

Joseph Domachowske1, Shabir A Madhi2, Eric A F Simões3, Victoria Atanasova4, Fernando Cabañas5, Kenji Furuno6, Maria L Garcia-Garcia7, Ineta Grantina8, Kim A Nguyen9, Dennis Brooks10, Yue Chang10, Amanda Leach10, Therese Takas10, Yuan Yuan10, M Pamela Griffin10, Vaishali S Mankad11, Tonya Villafana12.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35235733     DOI： 10.1056/NEJMc2112186

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

Review 1.  Challenges in Maximizing Impacts of Preventive Strategies against Respiratory Syncytial Virus (RSV) Disease in Young Children.

Authors:  Zhe Zheng
Journal:  Yale J Biol Med       Date:  2022-06-30

2.  Respiratory Syncytial Virus Is the Leading Cause of United States Infant Hospitalizations, 2009-2019: A Study of the National (Nationwide) Inpatient Sample.

Authors:  Mina Suh; Naimisha Movva; Xiaohui Jiang; Lauren C Bylsma; Heidi Reichert; Jon P Fryzek; Christopher B Nelson
Journal:  J Infect Dis       Date:  2022-08-15       Impact factor: 7.759

3.  Mortality Associated With Respiratory Syncytial Virus, Bronchiolitis, and Influenza Among Infants in the United States: A Birth Cohort Study From 1999 to 2018.

Authors:  Heidi Reichert; Mina Suh; Xiaohui Jiang; Naimisha Movva; Lauren C Bylsma; Jon P Fryzek; Christopher B Nelson
Journal:  J Infect Dis       Date:  2022-08-15       Impact factor: 7.759

4.  Respiratory Syncytial Virus Burden and Healthcare Utilization in United States Infants <1 Year of Age: Study of Nationally Representative Databases, 2011-2019.

Authors:  Mina Suh; Naimisha Movva; Xiaohui Jiang; Heidi Reichert; Lauren C Bylsma; Jon P Fryzek; Christopher B Nelson
Journal:  J Infect Dis       Date:  2022-08-15       Impact factor: 7.759

5.  Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model.

Authors:  Alexia Kieffer; Matthieu Beuvelet; Aditya Sardesai; Robert Musci; Sandra Milev; Julie Roiz; Jason K H Lee
Journal:  J Infect Dis       Date:  2022-08-15       Impact factor: 7.759

6.  The Burden of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Synthesis.

Authors:  Eric A F Simões
Journal:  J Infect Dis       Date:  2022-08-15       Impact factor: 7.759
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.